Related Experiment Video
Updated: Apr 11, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
[Familial hypercholesterolemia: why screening, counselling and treatment should be integrated]
Jeanine E Roeters van Lennep1, Frank L J Visseren, Petr E Jira
1*Namens de Nationale Werkgroep Familiaire Hypercholesterolemie, waarvan de leden aan het eind van dit artikel staan vermeld.
Insights
Familial hypercholesterolemia (FH) screening is crucial for preventing premature cardiovascular disease. Integrating FH detection, counseling, and treatment within routine healthcare ensures efficient and cost-effective patient care.
Area of Science:
- Genetics
- Cardiology
- Public Health
Background:
- Familial hypercholesterolemia (FH) is a common, inherited disorder causing high cholesterol and premature cardiovascular disease (CVD).
- Effective drug therapies are available for FH patients.
- The Netherlands previously pioneered a national FH screening program.
Purpose of the Study:
- To propose an integrated and cost-effective approach for Familial hypercholesterolemia (FH) detection, counseling, and treatment.
- To ensure continued efficient FH care following the discontinuation of the national screening program.
Main Methods:
- The study proposes integrating FH screening, counseling, and treatment coordination.
- This integration is suggested to be managed by healthcare providers currently treating FH patients.
Main Results:
- The discontinuation of the national screening program necessitates a new model for FH care.
- Integrating FH detection within existing healthcare structures is essential for efficiency.
Conclusions:
- Coordinated care by treating physicians can ensure efficient and cost-effective detection, counseling, and treatment of FH.
- This integrated approach aims to maintain the Netherlands' role in pioneering FH management.
Abstract:
Familial hypercholesterolemia (FH) is a monogenic autosomal dominant disorder. FH is the most common hereditary cause of raised serum cholesterol levels and is associated with an increased risk of premature cardiovascular disease (CVD). This disorder is known to have a genetic cause, and effective drug therapies exist for patients with FH. Successful cascade screening, within the framework of a national screening programme, gave the Netherlands an international role as model and pioneer as far as FH detection is concerned. With the ending of this screening programme as of 1 January 2014 the care for FH patients, including screening and counselling has had to be incorporated within the basic Dutch healthcare insurance system. It is essential that detection of FH should continue in as efficient and cost-effective a manner as possible. Our proposal is that this detection should be performed and co-ordinated by those treating patients with FH so that FH screening, counselling and treatment are integrated.
Related Concept Videos
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care

